Page 126

Marzo_2017

caso clínico 16. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis 396 induced by SGLT2 inhibitors: possible mechanism and contributing factors. Journal of Diabetes Investigation 2016; 7: 135-8. 17. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100(8): 2849-52. 18. Bode B, Garg S. The Emerging Role of Adjunctive Noninsulin Antihyperglycemic Therapy in the Mana- Cetoacidosis diabética asociada a ISGL T 2 - V. Novik et al gement of Type 1. Endocr Pract. 2016; 22: 220-30. 19. Peters A, Henry R, Thakkar P, Tong C, Alba M. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care 2016; 39: 532-38. 20. EMA makes recommendations to minimize ketoacidosis with SGLT2 inhibitors. Healthcare professionals should be aware of possible atypical cases. The Pharmaceutical Journal 2016; 296: 7886-8. Rev Med Chile 2017; 145: 393-396


Marzo_2017
To see the actual publication please follow the link above